AKT3 Polyclonal Antibody for IHC, WB, ELISA
Cat no : 21641-1-AP
AKT3, PKB GAMMA, PKBG, PRKBG, Protein kinase Akt 3, Protein kinase B gamma, RAC gamma, RAC PK gamma, STK 2
|Positive WB detected in||MCF7 cells, HeLa cells, human brain tissue, K-562 cells, NIH/3T3 cells|
|Positive IHC detected in||human kidney tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Western Blot (WB)||WB : 1:500-1:1000|
|Immunohistochemistry (IHC)||IHC : 1:20-1:200|
|Sample-dependent, check data in validation data gallery|
The 21641-1-AP immunogen is Fusion Protein AKT3 protein expressed in E. coli.
|Tested Reactivity||human, mouse, rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||AKT3 fusion protein Ag16298|
|Full Name||v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma)|
|Calculated molecular weight||465aa.54 kDa|
|Observed molecular weight||60 kDa|
|GenBank accession number||BC121154|
|Gene ID (NCBI)||10000|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
AKT3, also named as PKBG, is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. AKT3 is a key modulator of several tumors like melanoma, glioma and ovarian cancer. Active AKT3 increases progressively during melanoma tumor progression with highest levels present in advanced-stage metastatic melanomas.
J Cell Mol Med
EGR1 interacts with DNMT3L to inhibit the transcription of miR-195 and plays an anti-apoptotic role in the development of gastric cancer.
Long Non-coding RNA AK025387 Promotes Cell Migration and Invasion of Gastric Cancer.
MicroRNA-150 negatively regulates the function of CD4(+) T cells through AKT3/Bim signaling pathway.
MYO6 knockdown inhibits the growth and induces the apoptosis of prostate cancer cells by decreasing the phosphorylation of ERK1/2 and PRAS40.
J Ovarian Res
Role of BMI1 in epithelial ovarian cancer: investigated via the CRISPR/Cas9 system and RNA sequencing.
Cancer Cell Int
MiR-384 inhibits the proliferation of colorectal cancer by targeting AKT3.